Ophthalmologists had been enthusiastically using Genetech’s cancer drug Avastin, which cost about $50 a dose, to treat a common eye disease in the elderly, wet macular degeneration. Then Genentech introduced Lucentis, a nearly equivalent drug that cost $2,000 a dose and was approved specifically to treat the disease. Now, a new federal database shows that many of the doctors who were the top billers for Lucentis were also among the highest-paid consultants for Genentech, earning thousands of dollars to help promote the new drug. Eric Campbell, professor of medicine at Massachusetts General Hospital, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?